
Sepsis
Staging and Potential Future Therapies
Morgan & Claypool Publishers
Published on 11. September 2017
Book
Paperback/Softback
91 pages
978-1-61504-756-7 (ISBN)
Description
Sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to infection. Variability in pathogenesis and complex pathophysiology often delay diagnosis and create significant challenges for clinical studies in this group of critically ill patients. Mainly for those reasons, there is no therapy approved so far to overcome the underlying immune dysregulation. This book provides an overview about the state of the art of sepsis diagnostics and potential future therapies. Chapter 1 focuses on the immunologic staging of sepsis-the key for successful treatment of the dysregulated hot response. Chapter 2 reveals similarities in the immune response in sepsis and cancer-opening new avenues for novel therapies. Chapter 3 introduces an important modulator of the immune response-the endogenous cannabinoid system and elucidates its role in organ dysfunction in sepsis. Facing the increasing bacterial resistance to classical antibiotics, Chapter 4 discusses two unique mechanisms to treat infection and inflammation in sepsis: iron chelation, and the sphingosine pathway. The authors, all experts in experimental and clinical sepsis research, seek to provide further understanding of the complexities of the immune response as the physiological basis for the development of new therapeutics in sepsis.
More details
Series
Language
English
Place of publication
San Rafael
United States
Dimensions
Height: 235 mm
Width: 191 mm
Thickness: 6 mm
Weight
208 gr
ISBN-13
978-1-61504-756-7 (9781615047567)
Copyright in bibliographic data and cover images is held by Nielsen Book Services Limited or by the publishers or by their respective licensors: all rights reserved.
Schweitzer Classification
Persons
Dr. Christian Lehmann is Professor of Anesthesia, Pharmacology, Microbiology and Immunology, and Physiology and Biophysics at Dalhousie University, Halifax, NS, Canada. He is also Staff Anesthesiologist in the Department of Anesthesia, Nova Scotia Health Authority, Halifax. Dr. Lehmann has 25 years of experience in experimental and clinical inflammation research. He established experimental intravital imaging laboratories in Berlin and Greifswald, Germany. His focus of research is the microcirculation, i.e., capillary blood flow, cell-cell-interactions, and endothelial pathology. He participated in diverse German and international clinical multicenter trials, e.g., in sepsis. He joined Dalhousie University in 2007 and currently supervises research in three laboratories with modern equipment to study the microcirculation under various conditions experimentally and clinically. He is the author of more than 150 original publications, 13 book chapters and almost 200 published abstracts. He is a member of the Dalhousie Inflammation Group (DIG), the Microcirculation Diagnostics and Applied Studies (MiDAS) research group and the Cystic Fibrosis Translational Research (CFTR) group. In 2009, he founded the RESIST (Research in the Endocannabinoid System in Inflammation, Sepsis and Trauma) group with Dr. Melanie Kelly and others at Dalhousie University.
Author
Series Editor
Content
- Introduction
- Immunologic Staging of Sepsis: Finding the Right Lock for the Key
- Sepsis and Cancer: Similarities in the Immune Response and Treatment with Novel Therapies
- Organ Dysfunction and the Endocannabinoid System in Sepsis
- Novel Antibiotic Approaches in Sepsis
- Summary
- References
- Lead Author Biographies
- Contributing Author Biographies
- Immunologic Staging of Sepsis: Finding the Right Lock for the Key
- Sepsis and Cancer: Similarities in the Immune Response and Treatment with Novel Therapies
- Organ Dysfunction and the Endocannabinoid System in Sepsis
- Novel Antibiotic Approaches in Sepsis
- Summary
- References
- Lead Author Biographies
- Contributing Author Biographies